Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice
Open Access
- 21 November 2022
- journal article
- translational science
- Published by Portland Press Ltd. in Clinical Science
- Vol. 136 (22), 1661-1681
- https://doi.org/10.1042/cs20220607
Abstract
Cardiac hypertrophy is necessary for the heart to accommodate an increase in workload. Physiological, compensated hypertrophy (e.g. with exercise) is reversible and largely due to cardiomyocyte hypertrophy. Pathological hypertrophy (e.g. with hypertension) is associated with additional features including increased fibrosis and can lead to heart failure. RAF kinases (ARAF/BRAF/RAF1) integrate signals into the extracellular signal-regulated kinase 1/2 cascade, a pathway implicated in cardiac hypertrophy, and activation of BRAF in cardiomyocytes promotes compensated hypertrophy. Here, we used mice with tamoxifen-inducible cardiomyocyte-specific BRAF knockout (CM-BRAFKO) to assess the role of BRAF in hypertension-associated cardiac hypertrophy induced by angiotensin II (AngII; 0.8 mg/kg/d, 7 d) and physiological hypertrophy induced by phenylephrine (40 mg/kg/d, 7 d). Cardiac dimensions/functions were measured by echocardiography with histological assessment of cellular changes. AngII promoted cardiomyocyte hypertrophy and increased fibrosis within the myocardium (interstitial) and around the arterioles (perivascular) in male mice; cardiomyocyte hypertrophy and interstitial (but not perivascular) fibrosis were inhibited in mice with CM-BRAFKO. Phenylephrine had a limited effect on fibrosis but promoted cardiomyocyte hypertrophy and increased contractility in male mice; cardiomyocyte hypertrophy was unaffected in mice with CM-BRAFKO, but the increase in contractility was suppressed and fibrosis increased. Phenylephrine induced a modest hypertrophic response in female mice and, in contrast with the males, tamoxifen-induced loss of cardiomyocyte BRAF reduced cardiomyocyte size, had no effect on fibrosis and increased contractility. The data identify BRAF as a key signalling intermediate in both physiological and pathological hypertrophy in male mice, and highlight the need for independent assessment of gene function in females.Keywords
This publication has 55 references indexed in Scilit:
- Central Cardiovascular Circuits Contribute to the Neurovascular Dysfunction in Angiotensin II HypertensionJournal of Neuroscience, 2012
- Raf Family Kinases: Old Dogs Have Learned New TricksGenes & Cancer, 2011
- Extracellular Signal-Regulated Kinases 1 and 2 Regulate the Balance Between Eccentric and Concentric Cardiac GrowthCirculation Research, 2011
- Cre-loxP DNA recombination is possible with only minimal unspecific transcriptional changes and without cardiomyopathy in Tg(αMHC-MerCreMer) miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking TalePhysiological Reviews, 2010
- Functionally Opposing Roles of Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase in the Regulation of Cardiac ContractilityJournal of the American College of Cardiology, 2008
- Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivoProceedings of the National Academy of Sciences of the United States of America, 2007
- Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memoryJournal of Neuroscience Research, 2005
- Role of Raf Proteins in Cardiac Hypertrophy and Cardiomyocyte SurvivalTrends in Cardiovascular Medicine, 2005
- Hypertrophic Agonists Stimulate the Activities of the Protein Kinases c-Raf and A-Raf in Cultured Ventricular MyocytesOnline Journal of Public Health Informatics, 1995